Crystal Nucleation in Ibuprofen Glass: Possible Relevance Between the Characteristic Length of the Cooperatively Rearranging Region and the Size of Crystal Nuclei

Overview

Journal J Phys Chem B

Publisher American Chemical Society

Date 2025 Feb 6

PMID 39915259

Authors

Kohsaku Kawakami

Kaoru Ohyama

Affiliations

Soon will be listed here.

Abstract

Crystallization behavior of ibuprofen glass was investigated with focus on the nucleation process and its possible relevance to the cooperatively rearranging region (CRR). The nucleation temperature range of ibuprofen glass was determined by annealing it at various temperatures, followed by observation of the probability of cold crystallization. The temperature to provide the highest probability of nucleation was -15 °C. The effect of the addition of a polymer was also investigated to find that it enhanced and suppressed the crystallization depending on the polymer species and its amount added. The added polymer seemed to influence both nucleation and crystal growth processes by decreasing the glass/nuclei interfacial tension and increasing viscosity, respectively. In addition, the coincidence of the size of CRR in the presence of the polymer with the critical size of nuclei was assumed to enhance nucleation. This finding provides a novel viewpoint for clarifying the nucleation mechanism from supercooled liquids and glasses.

References

Kawakami K . Rigid Nuclei and Flexible Nuclei: Appearance and Disappearance of Nuclei in Indomethacin Glass Revealed by a Long-Term Annealing Study. J Phys Chem B. 2023; 127(26):5967-5977. DOI: 10.1021/acs.jpcb.3c02127. View

Dudognon E, Danede F, Descamps M, Correia N . Evidence for a new crystalline phase of racemic Ibuprofen. Pharm Res. 2008; 25(12):2853-8. DOI: 10.1007/s11095-008-9655-7. View

Rumondor A, Marsac P, Stanford L, Taylor L . Phase behavior of poly(vinylpyrrolidone) containing amorphous solid dispersions in the presence of moisture. Mol Pharm. 2009; 6(5):1492-505. DOI: 10.1021/mp900050c. View

Kawakami K . Modification of physicochemical characteristics of active pharmaceutical ingredients and application of supersaturatable dosage forms for improving bioavailability of poorly absorbed drugs. Adv Drug Deliv Rev. 2012; 64(6):480-95. DOI: 10.1016/j.addr.2011.10.009. View

Murdande S, Pikal M, Shanker R, Bogner R . Solubility advantage of amorphous pharmaceuticals: I. A thermodynamic analysis. J Pharm Sci. 2009; 99(3):1254-64. DOI: 10.1002/jps.21903. View

Wyttenbach N, Kuentz M . Glass-forming ability of compounds in marketed amorphous drug products. Eur J Pharm Biopharm. 2016; 112:204-208. DOI: 10.1016/j.ejpb.2016.11.031. View

Blaabjerg L, Lindenberg E, Lobmann K, Grohganz H, Rades T . Glass Forming Ability of Amorphous Drugs Investigated by Continuous Cooling and Isothermal Transformation. Mol Pharm. 2016; 13(9):3318-25. DOI: 10.1021/acs.molpharmaceut.6b00650. View

Newman A, Knipp G, Zografi G . Assessing the performance of amorphous solid dispersions. J Pharm Sci. 2012; 101(4):1355-77. DOI: 10.1002/jps.23031. View

Kawakami K . Supersaturation and crystallization: non-equilibrium dynamics of amorphous solid dispersions for oral drug delivery. Expert Opin Drug Deliv. 2016; 14(6):735-743. DOI: 10.1080/17425247.2017.1230099. View

10.

Song J, Kawakami K . Nucleation During Storage Impeded Supersaturation in the Dissolution Process of Amorphous Celecoxib. Mol Pharm. 2023; 20(8):4050-4057. DOI: 10.1021/acs.molpharmaceut.3c00210. View

11.

Kawakami K . Crystallization Tendency of Pharmaceutical Glasses: Relevance to Compound Properties, Impact of Formulation Process, and Implications for Design of Amorphous Solid Dispersions. Pharmaceutics. 2019; 11(5). PMC: 6572324. DOI: 10.3390/pharmaceutics11050202. View

12.

Kawakami K, Harada T, Yoshihashi Y, Yonemochi E, Terada K, Moriyama H . Correlation between glass-forming ability and fragility of pharmaceutical compounds. J Phys Chem B. 2015; 119(14):4873-80. DOI: 10.1021/jp509646z. View

13.

Kawakami K . Theory and practice of supersaturatable formulations for poorly soluble drugs. Ther Deliv. 2015; 6(3):339-52. DOI: 10.4155/tde.14.116. View

14.

Paudel A, Worku Z, Meeus J, Guns S, Van den Mooter G . Manufacturing of solid dispersions of poorly water soluble drugs by spray drying: formulation and process considerations. Int J Pharm. 2012; 453(1):253-84. DOI: 10.1016/j.ijpharm.2012.07.015. View

15.

Starr F, Douglas J . Modifying fragility and collective motion in polymer melts with nanoparticles. Phys Rev Lett. 2011; 106(11):115702. DOI: 10.1103/PhysRevLett.106.115702. View

16.

Baird J, Van Eerdenbrugh B, Taylor L . A classification system to assess the crystallization tendency of organic molecules from undercooled melts. J Pharm Sci. 2010; 99(9):3787-806. DOI: 10.1002/jps.22197. View

17.

Han X, Dai K, Kawakami K . Influence of Nucleation on Relaxation, Molecular Cooperativity, and Physical Stability of Celecoxib Glass. Mol Pharm. 2024; 21(4):1794-1803. DOI: 10.1021/acs.molpharmaceut.3c01116. View

18.

Descamps M, Dudognon E . Crystallization from the amorphous state: nucleation-growth decoupling, polymorphism interplay, and the role of interfaces. J Pharm Sci. 2014; 103(9):2615-2628. DOI: 10.1002/jps.24016. View